Leerink Partnrs Has Bearish Outlook for AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, November 3rd. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($3.86) per share for the year, down from their previous estimate of ($3.33). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.87) EPS and FY2026 earnings at $0.35 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics’s quarterly revenue was up 63.2% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on the company. Bank of America boosted their price objective on Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Royal Bank Of Canada boosted their target price on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a research note on Tuesday. Wells Fargo & Company cut their price target on shares of Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday. Finally, Guggenheim lifted their price objective on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $179.88.

Axsome Therapeutics Trading Down 0.9%

Shares of NASDAQ AXSM opened at $138.15 on Thursday. Axsome Therapeutics has a fifty-two week low of $75.56 and a fifty-two week high of $141.36. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -27.25 and a beta of 0.50. The business’s 50 day moving average price is $124.71 and its 200-day moving average price is $113.61.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Moors & Cabot Inc. increased its holdings in shares of Axsome Therapeutics by 4.5% in the 2nd quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock valued at $243,000 after acquiring an additional 100 shares during the period. Meridian Wealth Management LLC boosted its position in Axsome Therapeutics by 0.5% during the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after purchasing an additional 103 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after purchasing an additional 107 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Axsome Therapeutics by 6.1% in the third quarter. PNC Financial Services Group Inc. now owns 1,856 shares of the company’s stock worth $225,000 after purchasing an additional 107 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in Axsome Therapeutics by 0.6% in the third quarter. State of New Jersey Common Pension Fund D now owns 18,158 shares of the company’s stock worth $2,205,000 after purchasing an additional 109 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Insider Activity

In related news, COO Mark L. Jacobson sold 45,783 shares of Axsome Therapeutics stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $114.48, for a total value of $5,241,237.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 91,705 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at approximately $956,685.86. The trade was a 92.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 407,271 shares of company stock worth $50,640,415. Company insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.